Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi
The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Abstract
The emergence of drug-resistant fungi poses a major threat to human health. Despite advances in preventive, diagnostic, and therapeutic interventions, resistant fungal infections continue to cause significant morbidity and mortality in patients with compromised immunity, underscoring the urgent need for new antifungal agents. In this article, we review the challenges associated with identifying broad-spectrum antifungal drugs and highlight novel targets that could enhance the armamentarium of agents available to treat drug-resistant invasive fungal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404 · cited 1×
“of invasive candidiasis, using histone deacetylase (HDAC) as a target [125, 126].”
MethodDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“These agents, which are now widely used in clinical practice, inhibit the catalytic subunit of (1→3)-β-D-glucan synthase, which is responsible for biosynthesis of (1→3)-β-D-glucan, the major biopolymer of the fungal cell wall [20, 21].”
BackgroundSignal Transduction Cascades Regulating Fungal Development and Virulence
Lengeler, K. B., Davidson, R. C., D'souza, C., Harashima, T., Shen, W.-C., Wang, P., Pan, X., Waugh, M., & Heitman, J. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.4.746-785.2000 · Cited by 915
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans
P.B. Danielson, B. S. P. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337054 · Cited by 772
A Recently Evolved Transcriptional Network Controls Biofilm Development in Candida albicans
Nobile, C. J., Fox, E. P., Nett, J. E., Sorrells, T. R., Mitrovich, Q. M., Hernday, A. D., Tuch, B. B., Andes, D. R., & Johnson, A. D. (2012) · Cell · doi:10.1016/j.cell.2011.10.048 · Cited by 711
Noble, S. M., French, S., Kohn, L. A., Chen, V., & Johnson, A. D. (2010) · Nature Genetics · doi:10.1038/ng.605 · Cited by 678 · cited 1×
“The number of potential drug targets involving TFs continues to expand [121].”
BackgroundCritical Role of Bcr1-Dependent Adhesins in C. albicans Biofilm Formation In Vitro and In Vivo
Nobile, C. J., Andes, D. R., Nett, J. E., Smith, F. J., Yue, F., Phan, Q.-T., Edwards, J. E., Filler, S. G., & Mitchell, A. P. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020063 · Cited by 507 · cited 1×
“Zinc finger transcription factor Bcr1, encoded by BCR1, is one of the central regulators of biofilm formation, and bcr1/ bcr1 insertion and deletion mutants form only incomplete biofilms on silicone catheter material in vitro, suggesting a novel therapeutic target that interrupts adhesion [120].”
BackgroundHow to bolster the antifungal pipeline
Denning, D. W., & Bromley, M. J. (2015) · Science · doi:10.1126/science.aaa6097 · Cited by 481
Systematic Genetic Analysis of Virulence in the Human Fungal Pathogen Cryptococcus neoformans
Liu, O. W., Chun, C. D., Chow, E. D., Chen, C., Madhani, H. D., & Noble, S. M. (2008) · Cell · doi:10.1016/j.cell.2008.07.046 · Cited by 443
An insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432 · cited 1×
“Three classes of antifungal agents are currently available to clinicians to treat IFI: (1) triazoles that inhibit ergosterol biosynthesis (fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole); (2) the polyene amphotericin B-deoxycholate (its lipid and liposomal formulations), which binds fungal cell m…”
BackgroundEmerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416 · cited 1×
“In many cases, however, these agents carry drug- or class-specific toxicities, have major drug interactions, or are not sufficiently active because fungi have become resistant [2, 5, 6].”
BackgroundPerruccio, K., Tosti, A., Burchielli, E., Topini, F., Ruggeri, L., Carotti, A., Capanni, M., Urbani, E., Mancusi, A., Aversa, F., et al. (2005) · Blood · doi:10.1182/blood-2005-05-1775 · Cited by 391 · cited 1×
“Complementing these therapies are advances in innate host defense: a pioneering clinical study using adoptive transfer of Aspergillus-stimulated T cells showed significant efficacy in treating stem cell transplant recipients with invasive aspergillosis (9 of 10 treated patients cleared the infection vs 6 of 13 patient…”
BackgroundKontoyiannis, D. P., & Lewis, R. E. (2011) · Blood · doi:10.1182/blood-2011-03-316430 · Cited by 376 · cited 1×
“In many cases, however, these agents carry drug- or class-specific toxicities, have major drug interactions, or are not sufficiently active because fungi have become resistant [2, 5, 6].”
BackgroundSelf-citationAlonso-Monge, R., Navarro-García, F., Molero, G., Diez-Orejas, R., Gustin, M., Pla, J., Sánchez, M., & Nombela, C. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.10.3058-3068.1999 · Cited by 344
Verweij, P. E., Ananda-Rajah, M., Andes, D., Arendrup, M. C., Brüggemann, R. J., Chowdhary, A., Cornely, O. A., Denning, D. W., Groll, A. H., Izumikawa, K., et al. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.001 · Cited by 330
Self-citationLaFayette, S. L., Collins, C., Zaas, A. K., Schell, W. A., Betancourt-Quiroz, M., Gunatilaka, A. A. L., Perfect, J. R., & Cowen, L. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001069 · Cited by 329 · cited 1×
“may find clinical utility in combination therapy [78].”
BackgroundSelf-citationHarnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
Steinbach, W. J., Reedy, J. L., Cramer, R. A., Perfect, J. R., & Heitman, J. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1680 · Cited by 313
Major roles of isocitrate lyase and malate synthase in bacterial and fungal pathogenesis
Dunn, M. F., Ramírez-Trujillo, J. A., & Hernández-Lucas, I. (2009) · Microbiology · doi:10.1099/mic.0.030858-0 · Cited by 304
Life and death in a macrophage: role of the glyoxylate cycle in virulence
Lorenz, M. C., & Fink, G. R. (2002) · Eukaryotic Cell · doi:10.1128/ec.1.5.657-662.2002 · Cited by 300
Zhu, J., Huang, J.-W., Tseng, P.-H., Yang, Y.-T., Fowble, J., Shiau, C.-W., Shaw, Y.-J., Kulp, S. K., & Chen, C.-S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4063 · Cited by 258 · cited 1×
“AR-12 is a celecoxib derivative that has been tested in a phase 1 clinical trial as an anticancer agent, but it is not yet known whether AR-12 is sufficiently active to be clinically useful as an antifungal agent [73].”
BackgroundCompounds active against cell walls of medically important fungi
Hector, R. F. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.1.1 · Cited by 242 · cited 1×
“The echinocandins were among the first antifungals to target the fungal cell wall [19].”
BackgroundWinkler, A., Arkind, C., Mattison, C. P., Burkholder, A., Knoche, K., & Ota, I. (2002) · Eukaryotic Cell · doi:10.1128/ec.1.2.163-173.2002 · Cited by 242
MacPherson, S., Akache, B., Weber, S., De Deken, X., Raymond, M., & Turcotte, B. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1745-1752.2005 · Cited by 238 · cited 12×
“For example, adaptation to triazole therapy develops in C. albicans as the drug-stressed fungus compensates by up-regulating numerous stress-response genes in a process mediated Downloaded from https://academic.oup.com/jid/article-abstract/216/suppl_3/S474/4107051 by guest on 26 July 2018 S480 • JID 2017:216 (Suppl 3)…”
BackgroundInfluentialBioengineering T cells to target carbohydrate to treat opportunistic fungal infection
Kumaresan, P. R., Manuri, P. R., Albert, N. D., Maiti, S., Singh, H., Mi, T., Roszik, J., Rabinovich, B., Olivares, S., Krishnamurthy, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312789111 · Cited by 237 · cited 1×
“Infusion of D-CAR+ T cells reduced both fungal burden and mortality in 2 disparate (pulmonary, cutaneous) immunosuppressed murine models of aspergillosis [134].”
BackgroundSelf-citationNguyen, Q. B., Kadotani, N., Kasahara, S., Tosa, Y., Mayama, S., & Nakayashiki, H. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06242.x · Cited by 217
Systematic functional profiling of transcription factor networks in Cryptococcus neoformans
Jung, K.-W., Yang, D.-H., Maeng, S., Lee, K.-T., So, Y.-S., Hong, J., Choi, J., Byun, H.-J., Kim, H., Bang, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7757 · Cited by 203
In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200 · cited 1×
“cies except Candida krusei) and molds (Aspergillus species, Fusarium species, black molds), as well as strains resistant to triazoles and polyenes [14, 15].”
BackgroundDesign and optimization of highly-selective fungal CYP51 inhibitors
Hoekstra, W. J., Garvey, E. P., Moore, W. R., Rafferty, S. W., Yates, C. M., & Schotzinger, R. J. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.068 · Cited by 192 · cited 1×
“potency for the fungal CYP51 target [57].”
The fungal cell wall as a drug target
Georgopapadakou, N. (1995) · Trends in Microbiology · doi:10.1016/s0966-842x(00)88890-3 · Cited by 191 · cited 1×
“The fungal cell wall is both essential for fungi and absent from the mammalian host, making it the most easily accessible fungal-specific drug target (Figure 3) [10].”
BackgroundA complex task? Direct modulation of transcription factors with small molecules
Koehler, A. N. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.022 · Cited by 189
Antifungal Drug Discovery: Something Old and Something New
Butts, A., & Krysan, D. J. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002870 · Cited by 182 · cited 1×
“S476 • JID 2017:216 (Suppl 3) • McCarthy et al its antifungal activity by disrupting the mannoprotein outer layer of the cell wall and unmasking the more immunogenic inner β-glucan layer [18].”
BackgroundWarrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03707-14 · Cited by 173 · cited 7×
“Discovering new drugs for treatment of resistant IFIs is challenging because fungi are eukaryotes and far more closely related to humans than are bacteria or viruses.”
BackgroundInfluentialWatanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00731-11 · Cited by 169 · cited 1×
“in the GPI-anchoring pathway, responsible for inositol acylation (the mammalian homolog is not inhibited) [13].”
BackgroundSafety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161
Systems-level antimicrobial drug and drug synergy discovery
Roemer, T., & Boone, C. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1205 · Cited by 159 · cited 11×
“Discovering new drugs for treatment of resistant IFIs is challenging because fungi are eukaryotes and far more closely related to humans than are bacteria or viruses.”
BackgroundInfluentialCalcineurin-Crz1 Signaling in Lower Eukaryotes
Thewes, S. (2014) · Eukaryotic Cell · doi:10.1128/ec.00038-14 · Cited by 154
Nobile, C. J., Solis, N., Myers, C. L., Fay, A. J., Deneault, J.-S., Nantel, A., Mitchell, A. P., & Filler, S. G. (2008) · Cellular Microbiology · doi:10.1111/j.1462-5822.2008.01198.x · Cited by 150 · cited 1×
“albicans), suggesting potential drug targets [98, 99].”
Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149 · cited 2×
“The molecule was nontoxic at 100 mg/kg and was generally well tolerated at dosages of up to 300 mg/kg in rats [16].”
BackgroundConfronting the challenges of natural product-based antifungal discovery
Roemer, T., Xu, D., Singh, S. B., Parish, C. A., Harris, G., Wang, H., Davies, J. E., & Bills, G. F. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.009 · Cited by 147 · cited 1×
“New treatment options for IFIs are urgently needed, but it remains a challenge to bring novel agents to the market [135].”
BackgroundLawrence, C. L., Botting, C. H., Antrobus, R., & Coote, P. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3307-3323.2004 · Cited by 146
Zelter, A., Benčina, M., Bowman, B. J., Yarden, O., & Read, N. D. (2004) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2004.05.001 · Cited by 146 · cited 1×
“Among signaling pathways, disruption of calcium homeostasis appears uniquely promising for drug development [105, 106].”
BackgroundIdentification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids
Mor, V., Rella, A., Farnoud, A. M., Singh, A., Munshi, M., Bryan, A., Naseem, S., Konopka, J. B., Ojima, I., Bullesbach, E., et al. (2015) · mBio · doi:10.1128/mbio.00647-15 · Cited by 144 · cited 4×
“Two newly identified compounds, N′(3-bromo-4-hydroxybenzylidene)-2-methylbenzohydrazide (BHBM) and its derivative, 3-bromo-N′-(3-bromo-4-hydroxybenzylidene) benzohydrazide (D0), have been found to decrease levels of fungal but not mammalian GlcCer [43].”
BackgroundInfluentialPfaller, M. A., Messer, S. A., Georgopapadakou, N., Martell, L. A., Besterman, J. M., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00618-09 · Cited by 143 · cited 1×
“of invasive candidiasis, using histone deacetylase (HDAC) as a target [125, 126].”
MethodGWT1 Gene Is Required for Inositol Acylation of Glycosylphosphatidylinositol Anchors in Yeast
Umemura, M., Okamoto, M., Nakayama, K.-I., Sagane, K., Tsukahara, K., Hata, K., & Jigami, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301044200 · Cited by 127 · cited 1×
“E1210 is a novel isoxazolyl bis-pyridine wall-active antifungal compound (discovered by the Eisai Company in Japan) that inhibits an early step in the GPI-dependent anchoring of mannosylated cell wall proteins attached to the polysaccharide wall component [11, 12].”
BackgroundPreclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
Ong, V., Hough, G., Schlosser, M., Bartizal, K., Balkovec, J. M., James, K. D., & Krishnan, B. R. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-16 · Cited by 126
Kojima, K., Bahn, Y.-S., & Heitman, J. (2006) · Microbiology · doi:10.1099/mic.0.28571-0 · Cited by 125 · cited 1×
“which overactivates the HOG pathway and confers lethal effects [87].”
BackgroundEchinocandins and pneumocandins--a new antifungal class with a novel mode of action
Denning, D. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.5.611 · Cited by 124 · cited 1×
“These agents, which are now widely used in clinical practice, inhibit the catalytic subunit of (1→3)-β-D-glucan synthase, which is responsible for biosynthesis of (1→3)-β-D-glucan, the major biopolymer of the fungal cell wall [20, 21].”
BackgroundA comprehensive regulatory framework to address the unmet need for new antibacterial treatments
Rex, J. H., Eisenstein, B. I., Alder, J. D., Goldberger, M. J., Meyer, R., Dane, A. L., Friedland, I. R., Knirsch, C. A., Sanhai, W. R., Tomayko, J. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70293-1 · Cited by 123
Levery, S. B., Momany, M., Lindsey, R., Toledo, M. S., Shayman, J. A., Fuller, M., Brooks, K., Doong, R. L., Straus, A. H., & Takahashi, H. K. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03067-3 · Cited by 120 · cited 1×
“When yeast and mold lack the GSL called glucosylceramide (GlcCer), they are unable to replicate [41, 42].”
BackgroundTsukahara, K., Hata, K., Nakamoto, K., Sagane, K., Watanabe, N., Kuromitsu, J., Kai, J., Tsuchiya, M., Ohba, F., Jigami, Y., et al. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03481.x · Cited by 118 · cited 1×
“E1210 is a novel isoxazolyl bis-pyridine wall-active antifungal compound (discovered by the Eisai Company in Japan) that inhibits an early step in the GPI-dependent anchoring of mannosylated cell wall proteins attached to the polysaccharide wall component [11, 12].”
BackgroundMcLellan, C. A., Whitesell, L., King, O. D., Lancaster, A. K., Mazitschek, R., & Lindquist, S. (2012) · ACS Chemical Biology · doi:10.1021/cb300235m · Cited by 115 · cited 1×
“Gepinacin, a monocarboxylic amide, selectively inhibits Gwt1, a critical acyltransferase required for the biosynthesis of fungal GPI anchors [17].”
BackgroundIn Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine
Mitsuyama, J., Nomura, N., Hashimoto, K., Yamada, E., Nishikawa, H., Kaeriyama, M., Kimura, A., Todo, Y., & Narita, H. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01159-07 · Cited by 111
Cramer, K. L., Gerrald, Q. D., Nichols, C. B., Price, M. S., & Alspaugh, J. A. (2006) · Eukaryotic Cell · doi:10.1128/ec.00145-06 · Cited by 108 · cited 1×
“albicans), suggesting potential drug targets [98, 99].”
Divergent Targets of Candida albicans Biofilm Regulator Bcr1 In Vitro and In Vivo
Fanning, S., Xu, W., Solis, N., Woolford, C. A., Filler, S. G., & Mitchell, A. P. (2012) · Eukaryotic Cell · doi:10.1128/ec.00103-12 · Cited by 106 · cited 1×
“expression of cell surface genes to hyphal differentiation [118, 119].”
BackgroundPfaller, M. A., Messer, S. A., Rhomberg, P. R., Jones, R. N., & Castanheira, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw214 · Cited by 103
Cheah, H.-L., Lim, V., & Sandai, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095951 · Cited by 102
How Do Azoles Inhibit Cytochrome P450 Enzymes? A Density Functional Study
Balding, P. R., Porro, C. S., McLean, K. J., Sutcliffe, M. J., Maréchal, J., Munro, A. W., & de Visser, S. P. (2008) · The Journal of Physical Chemistry A · doi:10.1021/jp802087w · Cited by 102 · cited 1×
“S478 • JID 2017:216 (Suppl 3) • McCarthy et al triazole-class drugs work by selectively inhibiting fungal cytochrome P450 14α-demethylase [55].”
BackgroundLamoth, F., & Alexander, B. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00234-15 · Cited by 100 · cited 1×
“orally bioavailable glucan synthase inhibitors [30, 31].”
T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast
Shibata, T., Takahashi, T., Yamada, E., Kimura, A., Nishikawa, H., Hayakawa, H., Nomura, N., & Mitsuyama, J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05954-11 · Cited by 99 · cited 1×
“being evaluated in clinical trials [61].”
Lepak, A. J., Marchillo, K., & Andes, D. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04445-14 · Cited by 95 · cited 1×
“drugs are only available as intravenous therapies [29].”
BackgroundWring, S. A., Randolph, R., Park, S., Abruzzo, G., Chen, Q., Flattery, A., Garrett, G., Peel, M., Outcalt, R., Powell, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02068-16 · Cited by 94
In Vitro and In Vivo Antimalarial Activities of T-2307, a Novel Arylamidine
Kimura, A., Nishikawa, H., Nomura, N., Mitsuyama, J., Fukumoto, S., Inoue, N., & Kawazu, S.-I. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05856-11 · Cited by 93
Bae, M., Kim, H., Moon, K., Nam, S., Shin, J., Oh, K., & Oh, D. (2015) · Organic Letters · doi:10.1021/ol5037248 · Cited by 91 · cited 1×
“no cytotoxicity against the tested human carcinoma cell lines (A549, HCT116, SNU638, K562, SK-HEP1, or MDA-MB231), suggesting a pathway for ICL inhibitor design [51].”
BackgroundGarcía, R., Botet, J., Rodríguez-Peña, J. M., Bermejo, C., Ribas, J. C., Revuelta, J. L., Nombela, C., & Arroyo, J. (2015) · BMC Genomics · doi:10.1186/s12864-015-1879-4 · Cited by 91 · cited 1×
“be the most promising as it is the main signal transduction system that is responsible for cellular stress responses [83, 84].”
BackgroundSCY-078 is fungicidal against Candida species in time-kill studies
Scorneaux, B., Angulo, D., Borroto-Esoda, K., Ghannoum, M., Peel, M., & Wring, S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01961-16 · Cited by 88
Regulatory Role of Glycerol in Candida albicans Biofilm Formation
Desai, J. V., Bruno, V. M., Ganguly, S., Stamper, R. J., Mitchell, K. F., Solis, N., Hill, E. M., Xu, W., Filler, S. G., Andes, D. R., et al. (2013) · mBio · doi:10.1128/mbio.00637-12 · Cited by 87 · cited 1×
“expression of cell surface genes to hyphal differentiation [118, 119].”
BackgroundLohberger, A., Coste, A. T., & Sanglard, D. (2014) · Eukaryotic Cell · doi:10.1128/ec.00245-13 · Cited by 85 · cited 1×
“murine macrophages, which may at least partially explain the virulence defects [117].”
BackgroundStress Signaling Pathways for the Pathogenicity of Cryptococcus
Bahn, Y.-S., & Jung, K.-W. (2013) · Eukaryotic Cell · doi:10.1128/ec.00218-13 · Cited by 84 · cited 2×
“the HOG pathway could be more efficient at killing a pathogen than those targeting its positive regulators [76].”
BackgroundKoselny, K., Green, J., DiDone, L., Halterman, J. P., Fothergill, A. W., Wiederhold, N. P., Patterson, T. F., Cushion, M. T., Rappelye, C., Wellington, M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-16 · Cited by 83 · cited 1×
“neoformans), molds (eg, Fusarium, Mucor), and dimorphic fungi (Blastomyces, Histoplasma, and Coccidioides) with MICs of 2–4 μg/mL [72].”
BackgroundCD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81 · cited 1×
“Antifungal susceptibility testing performed on a collection of 95 Candida strains including 30 caspofungin‐resistant isolates containing fks mutations demonstrated comparable antifungal potency of CD101 relative to the echinocandin micafungin [25].”
BackgroundEbel, F., Schwienbacher, M., Beyer, J., Heesemann, J., Brakhage, A. A., & Brock, M. (2006) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2006.01.015 · Cited by 81 · cited 1×
“fumigatus), making it a promising target for the development of novel antifungal agents [48].”
BackgroundKamran, M., Calcagno, A.-M., Findon, H., Bignell, E., Jones, M. D., Warn, P., Hopkins, P., Denning, D. W., Butler, G., Rogers, T., et al. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.2.546-552.2004 · Cited by 75
The anti-Aspergillus drug pipeline: Is the glass half full or empty?: Table 1.
Osherov, N., & Kontoyiannis, D. P. (2017) · Medical Mycology · doi:10.1093/mmy/myw060 · Cited by 74 · cited 2×
“ASP2397 is a novel cyclic hexapeptide antifungal agent isolated by Astellas Pharma in Japan from an Acremonium species and now under development by Vical Inc [8].”
BackgroundMethodSelf-citationJames, K. D., Laudeman, C. P., Malkar, N. B., Krishnan, R., & Polowy, K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01541-16 · Cited by 73
Mayr, A., & Lass-Flörl, C. (2011) · European Journal of Medical Research · doi:10.1186/2047-783x-16-4-153 · Cited by 70
Román, E., Alonso-Monge, R., Gong, Q., Li, D., Calderone, R., & Pla, J. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00545.x · Cited by 70 · cited 1×
“that allow adaptation to environmental changes and is evolutionarily conserved from yeasts to mammals [75].”
BackgroundFunctional Analyses of Two Acetyl Coenzyme A Synthetases in the Ascomycete Gibberella zeae
Lee, S., Son, H., Lee, J., Min, K., Choi, G. J., Kim, J.-C., & Lee, Y. (2011) · Eukaryotic Cell · doi:10.1128/ec.05071-11 · Cited by 70 · cited 1×
“Acetyl coenzyme A (acetyl-CoA) is a crucial metabolite for fungal energy metabolism and biosynthetic pathways that is produced in various cellular compartments [70, 71].”
BackgroundChitin synthases in yeast and fungi
Valdivieso, M. ‐., Durán, Á., & Roncero, C. (1999) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8757-1_4 · Cited by 69
Systemic Antifungal Agents: Current Status and Projected Future Developments
Seyedmousavi, S., Rafati, H., İlkit, M., Tolooe, A., Hedayati, M. T., & Verweij, P. E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6515-1_5 · Cited by 68 · cited 1×
“orally bioavailable glucan synthase inhibitors [30, 31].”
Pfaller, M. A., Rhomberg, P. R., Messer, S. A., & Castanheira, M. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.11.008 · Cited by 67 · cited 1×
“a potential role for combination therapy in vivo [128].”
BackgroundFungal‐specific transcription factor A b P f2 activates pathogenicity in A lternaria brassicicola
Cho, Y., Ohm, R. A., Grigoriev, I. V., & Srivastava, A. (2013) · The Plant Journal · doi:10.1111/tpj.12217 · Cited by 67
Chemical approaches to transcriptional regulation
Majmudar, C. Y., & Mapp, A. K. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.08.012 · Cited by 66
Guimaraes, L. L., Toledo, M. S., Ferreira, F. A. S., Straus, A. H., & Takahashi, H. K. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00138 · Cited by 64 · cited 1×
“When yeast and mold lack the GSL called glucosylceramide (GlcCer), they are unable to replicate [41, 42].”
BackgroundShubitz, L. F., Trinh, H. T., Perrill, R. H., Thompson, C. M., Hanan, N. J., Galgiani, J. N., & Nix, D. E. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu029 · Cited by 63 · cited 1×
“Nikkomycin X and nikkomycin Z are structurally similar antifungal agents produced by both Streptomyces ansochromogenes and Streptomyces tendae, and have activity against a variety of human fungal pathogens [37, 38].”
BackgroundSurvival Strategies of Yeast and Filamentous Fungi against the Antifungal Protein AFP
Ouedraogo, J., Hagen, S., Spielvogel, A., Engelhardt, S., & Meyer, V. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.203588 · Cited by 63 · cited 1×
“The calcium-selective, membrane-impermeable chelator BAPTA did not influence the resting level of intracellular calcium, suggesting that it could selectively disrupt the calcium cell survival pathway [104].”
BackgroundBinder, U., Benčina, M., Eigentler, A., Meyer, V., & Marx, F. (2011) · BMC Microbiology · doi:10.1186/1471-2180-11-209 · Cited by 63 · cited 1×
“nidulans and Aspergillus niger, by inducing the rapid influx of extracellular calcium [103].”
BackgroundMariette, C., Tavernier, E., Hocquet, D., Huynh, A., Isnard, F., Legrand, F., Lhéritier, V., Raffoux, E., Dombret, H., Ifrah, N., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1204652 · Cited by 62 · cited 1×
“IFIs continue to be an important cause of morbidity and mortality, particularly in immunocompromised patients [130].”
BackgroundKoselny, K., Green, J., Favazzo, L., Glazier, V. E., DiDone, L., Ransford, S., & Krysan, D. J. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00134 · Cited by 61 · cited 1×
“Acetyl coenzyme A (acetyl-CoA) is a crucial metabolite for fungal energy metabolism and biosynthetic pathways that is produced in various cellular compartments [70, 71].”
BackgroundHistone deacetylase inhibition as an alternative strategy against invasive aspergillosis
Lamoth, F., Juvvadi, P. R., & Steinbach, W. J. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00096 · Cited by 61
Maier, E. J., Haynes, B. C., Gish, S. R., Wang, Z. A., Skowyra, M. L., Marulli, A. L., Doering, T. L., & Brent, M. R. (2015) · Genome Research · doi:10.1101/gr.184101.114 · Cited by 60 · cited 1×
“numerous infectivity-related TFs, suggesting that a host of novel antifungal targets may exist [124].”
BackgroundTwo-Component Signal Transduction Proteins as Potential Drug Targets in Medically Important Fungi
Chauhan, N., & Calderone, R. (2008) · Infection and Immunity · doi:10.1128/iai.00834-08 · Cited by 60 · cited 1×
“transduction network is composed of a 2-component-system– like phosphorelay system and the Hog1-type MAPK cascade [85].”
BackgroundBaxter, B. K., DiDone, L., Ogu, D., Schor, S., & Krysan, D. J. (2011) · ACS Chemical Biology · doi:10.1021/cb100399x · Cited by 59 · cited 1×
“ity via disruption of cell wall signaling [91].”
BackgroundPiekarska, K., Hardy, G., Mol, E., van den Burg, J., Strijbis, K., van Roermund, C., van den Berg, M., & Distel, B. (2008) · Microbiology · doi:10.1099/mic.0.2008/020289-0 · Cited by 59
Efficacy of nikkomycin Z against experimental pulmonary blastomycosis
Clemons, K. V., & Stevens, D. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.2026 · Cited by 59 · cited 1×
“Nikkomycin X and nikkomycin Z are structurally similar antifungal agents produced by both Streptomyces ansochromogenes and Streptomyces tendae, and have activity against a variety of human fungal pathogens [37, 38].”
BackgroundOn the Mechanism of Action of the Myxobacterial Fungicide Ambruticin.
KNAUTH, P., & Reichenbach, H. (2000) · The Journal of Antibiotics · doi:10.7164/antibiotics.53.1182 · Cited by 58 · cited 1×
“Other compounds targeting the HOG system have been identified including the ambruticins, a family of cyclopropyl-pyran acids with broad antifungal activity [88].”
BackgroundNew developments and directions in the clinical application of the echinocandins
Chang, C. C., Slavin, M. A., & Chen, S. C. A. (2017) · Archives of Toxicology · doi:10.1007/s00204-016-1916-3 · Cited by 56 · cited 1×
“The stability properties also suggest that CD101 may be of use as a topical agent [27, 28].”
BackgroundLee, H., Yoon, K., Han, Y., Lee, K. J., Chung, S., Kim, T., Lee, S., Shin, J., & Oh, K. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.01.017 · Cited by 56 · cited 1×
“ically suitable for use in vivo due to their toxicity [49].”
BackgroundEvaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models
Shubitz, L. F., Trinh, H. T., Galgiani, J. N., Lewis, M. L., Fothergill, A. W., Wiederhold, N. P., Barker, B. M., Lewis, E. R. G., Doyle, A. L., Hoekstra, W. J., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00593-15 · Cited by 55 · cited 1×
“concentration required to inhibit growth of 50% of organisms and minimum inhibitory concentration required to inhibit 90% of organisms values of 1 and 2 μg/mL, respectively, against 52 Coccidioides clinical isolates [58].”
BackgroundPotential Targets for Antifungal Drug Discovery Based on Growth and Virulence in Candida albicans
Li, X., Hou, Y., Yue, L., Liu, S., Du, J., & Sun, S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00726-15 · Cited by 54 · cited 1×
“ponents with lower host immunosuppressive cross-reactivity [100].”
Pfaller, M. A., Watanabe, N., Castanheira, M., Messer, S. A., & Jones, R. N. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr342 · Cited by 50 · cited 1×
“cies except Candida krusei) and molds (Aspergillus species, Fusarium species, black molds), as well as strains resistant to triazoles and polyenes [14, 15].”
BackgroundJiang, Z., Liu, N., Hu, D., Dong, G., Miao, Z., Yao, J., He, H., Jiang, Y., Zhang, W., Wang, Y., et al. (2015) · Chemical Communications · doi:10.1039/c5cc05699c · Cited by 50 · cited 1×
“Structural simplification of the natural product sampangine led to the discovery of 2 novel antifungal lead compounds [69].”
BackgroundTriazole resistance in Aspergillus fumigatus isolates from patients with cystic fibrosis in Italy
Prigitano, A., Esposto, M. C., Biffi, A., Lorenzis, G. D., Favuzzi, V., Koncan, R., Cascio, G. L., Barao, M. O., Colombo, C., Pizzamiglio, G., et al. (2016) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2016.06.006 · Cited by 50
Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., Bocanegra, R., Olivo, M., McCarthy, D. I., Fukuda, Y., Mitsuyama, J., & Patterson, T. F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv398 · Cited by 48
The transmembrane protein Opy2 mediates activation of the Cek1 MAP kinase in Candida albicans
Herrero-de-Dios, C. M., Román, E., Diez, C., Alonso‐Monge, R., & Plá, J. (2012) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2012.11.001 · Cited by 48
Booth, L. A., Roberts, J. L., Tavallai, M., Nourbakhsh, A., Chuckalovcak, J., Carter, J., Poklepovic, A. S., & Dent, P. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24977 · Cited by 47 · cited 1×
“OSU-0312 has recently advanced to early-phase clinical trials [92].”
BackgroundArgimón, S., Fanning, S., Blankenship, J. R., & Mitchell, A. P. (2011) · Eukaryotic Cell · doi:10.1128/ec.00133-10 · Cited by 46
Exploiting Fungal Virulence-Regulating Transcription Factors As Novel Antifungal Drug Targets
Bahn, Y.-S. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004936 · Cited by 44
Cell wall protection by the Candida albicans class I chitin synthases
Preechasuth, K., Anderson, J. C., Peck, S. C., Brown, A. J. P., Gow, N. A. R., & Lenardon, M. D. (2015) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2015.08.001 · Cited by 43 · cited 1×
“Another important component of the fungal cell wall is the polysaccharide chitin, which is produced by chitin synthase [34, 35].”
BackgroundA comparative genomic analysis of calcium and proton signaling/homeostasis in Aspergillus species
Benčina, M., Bagar, T., Lah, L., & Kraševec, N. (2009) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2008.07.019 · Cited by 41 · cited 1×
“Among signaling pathways, disruption of calcium homeostasis appears uniquely promising for drug development [105, 106].”
BackgroundTranscriptional Switches: Chemical Approaches to Gene Regulation
Lee, L. W., & Mapp, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.075044 · Cited by 41
Emerging drugs and vaccines for Candidemia
Moriyama, B., Gordon, L. A., McCarthy, M., Henning, S. A., Walsh, T. J., & Penzak, S. R. (2014) · Mycoses · doi:10.1111/myc.12265 · Cited by 37 · cited 6×
“developing several metalloenzyme inhibitors of CYP51 including VT-1598, VT-1129, and VT-1161 [1].”
BackgroundInfluentialSelf-citationBoikov, D. A., Locke, J. B., James, K. D., Bartizal, K., & Sobel, J. D. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx008 · Cited by 37 · cited 1×
“The stability properties also suggest that CD101 may be of use as a topical agent [27, 28].”
BackgroundTreatment Principles for the Management of Mold Infections
Kontoyiannis, D. P., & Lewis, R. E. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019737 · Cited by 37
Self-citationLevine, H. B., Ringel, S. M., & Cobb, J. M. (1978) · CHEST Journal · doi:10.1378/chest.73.2.202 · Cited by 36 · cited 1×
“Ambruticin S, an antifungal cyclopropyl-pyran acid, has long been known to have curative effects against murine pulmonary coccidioidal infection [89].”
BackgroundArendrup, M. C., Hare, R. K., & Cuenca‐Estrella, M. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02336-15 · Cited by 35 · cited 1×
“different from that of licensed antifungal agents and has activity against Aspergillus species and Candida glabrata [60].”
BackgroundSmall-Molecule Chromatin-Modifying Agents: Therapeutic Applications
Mai, A. (2010) · Epigenomics · doi:10.2217/epi.10.7 · Cited by 35 · cited 1×
“lular functions, ranging from cell proliferation to cell death, by regulating chromatin structure and transcription through lysine deacetylation of histones [127].”
BackgroundGallo-Ebert, C., Donigan, M., Stroke, I. L., Swanson, R. N., Manners, M. T., Francisco, J., Toner, G., Gallagher, D., Huang, C.-Y., Gygax, S. E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01677-13 · Cited by 32
Welsch, C. A., Roth, L., Goetschy, J., & Movva, N. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406179200 · Cited by 29
The Calcium Channel Blocker Verapamil Inhibits Oxidative Stress Response in Candida albicans
Yu, Q., Xiao, C., Zhang, K., Jia, C., Ding, X., Zhang, B., Wang, Y., & Li, M. (2014) · Mycopathologia · doi:10.1007/s11046-014-9735-7 · Cited by 29 · cited 1×
“Calcium signaling is closely associated with numerous physiological processes in fungi, including stress responses, virulence, hyphal development, and adhesion [93, 94].”
BackgroundGlycosphingolipids of human embryonic stem cells
Breimer, M. E., Säljö, K., Barone, A., & Teneberg, S. (2016) · Glycoconjugate Journal · doi:10.1007/s10719-016-9706-y · Cited by 29 · cited 1×
“in a variety of fungi [40] (Figures 2 and 3).”
BackgroundKonte, T., & Plemenitaš, A. (2013) · Extremophiles · doi:10.1007/s00792-013-0546-4 · Cited by 28 · cited 1×
“be the most promising as it is the main signal transduction system that is responsible for cellular stress responses [83, 84].”
BackgroundDinér, P., Vilg, J. V., Kjellén, J., Migdal, I., Andersson, T., Gebbia, M., Giaever, G. N., Nislow, C., Hohmann, S., Wysocki, R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020012 · Cited by 27
Yaakov, D. B., Rivkin, A., Mircus, G., Albert, N. D., Dietl, A., Kovalerchick, D., Carmeli, S., Haas, H., Kontoyiannis, D. P., & Osherov, N. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv446 · Cited by 27
Self-citationSampangine Inhibits Heme Biosynthesis in both Yeast and Human
Huang, Z., Chen, K., Xu, T., et al. (2011) · Eukaryotic Cell · doi:10.1128/ec.05170-11 · Cited by 26 · cited 1×
“antifungal activity through inhibition of heme biosynthesis [67].”
BackgroundYamada, E., Nishikawa, H., Nomura, N., & Mitsuyama, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00355-10 · Cited by 26
Fingolimod (FTY720) Stimulates Ca2+/Calcineurin Signaling in Fission Yeast
Hagihara, K., Kita, A., Mizukura, A., Yao, M., Kitai, Y., Kunoh, T., Masuko, T., Matzno, S., Chiba, K., & Sugiura, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081907 · Cited by 25
Efficacy of Ambruticin Analogs in a Murine Model of Coccidioidomycosis
Shubitz, L. F., Galgiani, J. N., Tian, Z.-Q., Zhong, Z., Timmermans, P. B. M. W. M., & Katz, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00670-06 · Cited by 23 · cited 1×
“Recently, 2 analogs of ambruticin S with greater in vitro potency, KOSN-2079 and KOSN-2089, were tested against lethal murine Coccidioides infection; both improved the survival of mice over that of controls, suggesting that larger studies in animals may be warranted [90].”
BackgroundMircus, G., Albert, N. D., Yaakov, D. B., Chikvashvili, D., Shadkchan, Y., Kontoyiannis, D. P., & Osherov, N. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00850-15 · Cited by 22
Self-citationOberdorfer, G., Binter, A., Ginj, C., Macheroux, P., & Gruber, K. F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.352096 · Cited by 15 · cited 1×
“Nikkomycins are a group of peptidyl nucleoside antimicrobial agents that act as competitive inhibitors of chitin synthase and inhibit the growth of filamentous fungi and yeasts [36].”
BackgroundMahdi, F., Morgan, J. B., Liu, W., Agarwal, A. K., Jekabsons, M. B., Liu, Y., Zhou, Y., & Nagle, D. G. (2015) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00819 · Cited by 13 · cited 1×
“III synthase to inhibit heme biosynthesis [68].”
Cited by
Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400
Immune defence to invasive fungal infections: A comprehensive review
Pathakumari, B., Liang, G., & Liu, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110550 · Cited by 264
Aspiring Antifungals: Review of Current Antifungal Pipeline Developments
Gintjee, T., Donnelley, M., & Thompson, G. (2020) · Journal of Fungi · doi:10.3390/jof6010028 · Cited by 225
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
Sobel, J. D., & Sobel, R. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1476490 · Cited by 168
von Lilienfeld-Toal, M., Wagener, J., Einsele, H., Cornely, O. A., & Kurzai, O. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0271 · Cited by 164
Self-citation
Metadata
- Authors
- McCarthy, M. W., Kontoyiannis, D. P., Cornely, O. A., Perfect, J. R., & Walsh, T. J.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-15
- Volume
- 216
- Issue
- suppl_3
- Pages
- S474-S483
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2751530162
- Cited by
- 169
- References
- 131
- FWCI
- 15.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.